Literature DB >> 32776393

An MRI-Based Radiomic Nomogram for Discrimination Between Malignant and Benign Sinonasal Tumors.

Han Zhang1, Hexiang Wang1, Dapeng Hao1, Yaqiong Ge2, Guangyao Wan1, Jun Zhang1, Shunli Liu1, Yu Zhang1, Deguang Xu3.   

Abstract

BACKGROUND: Preoperative discrimination between malignant and benign sinonasal tumors is important for treatment plan selection.
PURPOSE: To build and validate a radiomic nomogram for preoperative discrimination between malignant and benign sinonasal tumors. STUDY TYPE: Retrospective. POPULATION: In all, 197 patients with histopathologically confirmed 84 benign and 113 malignant sinonasal tumors. FIELD STRENGTH/SEQUENCES: Fast-spin-echo (FSE) T1 -weighted and fat-suppressed FSE T2 -weighted imaging on a 1.5T and 3.0T MRI. ASSESSMENT: T1 and fat-suppressed T2 -weighted images were selected for feature extraction. The least absolute shrinkage selection operator (LASSO) algorithm was applied to establish a radiomic score. Multivariate logistic regression analysis was applied to determine independent risk factors, and the radiomic score was combined to build a radiomic nomogram. The nomogram was assessed in a training dataset (n = 138/3.0T MRI) and tested in a validation dataset (n = 59/1.5T MRI). STATISTICAL TESTS: Independent t-test or Wilcoxon's test, chi-square-test, or Fisher's-test, univariate analysis, LASSO, multivariate logistic regression analysis, area under the curve (AUC), Hosmer-Lemeshow test, decision curve, and the Delong test.
RESULTS: In the validation dataset, the radiomic nomogram could differentiate benign from malignant sinonasal tumors with an AUC of 0.91. There was no significant difference in AUC between the combined radiomic score and radiomic nomogram (P > 0.05), and the radiomic nomogram showed a relatively higher AUC than the combined radiomic score. There was a significant difference in AUC between each two of the following models (the radiomic nomogram vs. the clinical model, all P < 0.001; the combined radiomic score vs. the clinical model, P = 0.0252 and 0.0035, respectively, in the training and validation datasets). The radiomic nomogram outperformed the radiomic scores and clinical model. DATA
CONCLUSION: The radiomic nomogram combining the clinical model and radiomic score is a simple, effective, and reliable method for patient risk stratification. LEVEL OF EVIDENCE: 4 TECHNICAL EFFICACY STAGE: 2.
© 2020 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  diagnosis; head and neck neoplasms; magnetic resonance imaging; radiomic

Mesh:

Year:  2020        PMID: 32776393     DOI: 10.1002/jmri.27298

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  4 in total

1.  A Clinical-Radiomics Nomogram Based on the Apparent Diffusion Coefficient (ADC) for Individualized Prediction of the Risk of Early Relapse in Advanced Sinonasal Squamous Cell Carcinoma: A 2-Year Follow-Up Study.

Authors:  Naier Lin; Sihui Yu; Mengyan Lin; Yiqian Shi; Wei Chen; Zhipeng Xia; Yushu Cheng; Yan Sha
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

2.  Radiomics Nomograms Based on Multi-Parametric MRI for Preoperative Differential Diagnosis of Malignant and Benign Sinonasal Tumors: A Two-Centre Study.

Authors:  Shu-Cheng Bi; Han Zhang; He-Xiang Wang; Ya-Qiong Ge; Peng Zhang; Zhen-Chang Wang; Da-Peng Hao
Journal:  Front Oncol       Date:  2021-05-03       Impact factor: 6.244

3.  Machine learning-based multiparametric MRI radiomics for predicting poor responders after neoadjuvant chemoradiotherapy in rectal Cancer patients.

Authors:  Jia Wang; Jingjing Chen; Ruizhi Zhou; Yuanxiang Gao; Jie Li
Journal:  BMC Cancer       Date:  2022-04-19       Impact factor: 4.638

4.  MRI radiomics-based machine learning model integrated with clinic-radiological features for preoperative differentiation of sinonasal inverted papilloma and malignant sinonasal tumors.

Authors:  Jinming Gu; Qiang Yu; Quanjiang Li; Juan Peng; Fajin Lv; Beibei Gong; Xiaodi Zhang
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.